Harpoon Therapeutics, Inc
4000 Shoreline Court, Suite 250
South San Francisco
CA
94080
United States
121 articles with Harpoon Therapeutics, Inc
-
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
3/14/2023
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.
-
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
2/7/2023
Harpoon Therapeutics, Inc. today announced that management will present at the virtual SVB Securities Global Biopharma Conference.
-
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
12/11/2022
Harpoon Therapeutics, Inc. presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person and virtually in New Orleans.
-
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
12/5/2022
Harpoon Therapeutics, Inc. today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update.
-
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.
-
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
11/14/2022
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided an update on strategic priorities and reported financial results for the third quarter ended September 30, 2022.
-
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
11/3/2022
Harpoon Therapeutics, Inc. announced that it will present updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person in New Orleans, Louisiana and virtually from December 10-13, 2022.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical OfficerHarpoon adds experienced drug developer to leadership team
10/4/2022
Harpoon Therapeutics, Inc. today announced the appointment of Luke Walker, M.D., as Chief Medical Officer.
-
Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
9/19/2022
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced the appointment of Lauren Silvernail to its Board of Directors and as the Chairperson of its Audit Committee.
-
Harpoon Therapeutics to Participate in Three Upcoming September 2022 Investor Conferences
9/1/2022
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in three upcoming investor conferences:
-
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/10/2022
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences - Aug 02, 2022
8/2/2022
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in two upcoming investor conferences:
-
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.
-
Harpoon Therapeutics Expands Leadership Team
7/6/2022
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine.
-
Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
5/26/2022
Harpoon Therapeutics, Inc. (Nasdaq: HARP), today announced interim safety and efficacy data from the ongoing dose escalation and expansion study evaluating HPN328, Harpoon’s half-life extended TriTAC® targeting delta-like canonical Notch ligand 3 (DLL3), for the treatment of SCLC and other neuroendocrine cancers.
-
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
5/2/2022
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the Company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.
-
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome
4/12/2022
Harpoon Therapeutics, Inc. today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting being held in New Orleans from April 8-13, 2022.
-
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
4/7/2022
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.